At a glance
ClinicalIndex Comparison Record- ✓Sarcomatoid or sarcomatoid-dominant (>50%) biphasic pleural mesothelioma
- ✓Stage I-IIIA disease per UICC TNM 8th edition
- ✓Age ≥18 years
- ✓ECOG performance status ≤2 or Karnofsky ≥60%
- ✕Patients deemed unresectable or poor surgical candidates
- ✕Chest wall invasion, peritoneal spread, contralateral pleural involvement, mediastinal organ involvement, vertebral involvement, contralateral intrathoracic lymph node metastases, or supraclavicular node involvement
- ✕History of symptomatic interstitial lung disease
- ✕Prior treatment for primary neoplasm or treatment that would impact primary endpoint
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Official Title Neoadjuvant Immunotherapy in Sarcomatoid Mesothelioma
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Ipilimumab, and 4 other interventions for Pleural Biphasic Mesothelioma and Pleural Sarcomatoid Mesothelioma. Currently recruiting, targeting 26 participants across 132 sites.
Signals
Detailed Summary
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.
Study Details
Timeline
Arms & Interventions
Patients receive nivolumab IV, ipilimumab IV, and may undergo surgery on study. Patients also undergo CT or MRI and PET throughout the trial.
Interventions
Given IV
Given IV
Undergo surgery
undergo CT
Undergo MRI
Undergo PET